1. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 2009; 4: 9–17.
2. Anthonisen NR, Connet JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9.
3. Sidney S, Sorel M, Quesenberry CP et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75.
4. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567–72.
5. Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8–11.
6. Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Int Med 1989; 149: 2414e20.
7. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335e48.
8. Worth H, Chung KF, Felser JM et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105 (4): 571–9.
9. Lee TA, Simon A, Pickard AS et al. Risk of death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380–90.
10. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. J Am Med Assoc 2008; 300: 1439–50.
11. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013; 68 (1): 114–6.
12. Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010; 9: 783–92.
13. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
14. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364 (12): 1093–103.
15. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009; 103 (10): 1421–9.
16. Kesten S, Jara M, Wentworth C, Lanes S et al. Pooled Clinical Trial Analysis of Tiotropium Safety. Chest December 2006; 130: 1695–703.
17. Kesten S, Celli B, Decramer M et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009; 4: 397–409.
18. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137 (1): 20–30.
19. Gershon AS, Wang L, To T et al. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease. COPD 2008; 5 (4): 229–34.
20. De Luise C, Lanes SF, Jacobsen J et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267–72.
21. Verhamme KM, Afonso AS, van Noord C et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 2012; 25 (1): 19–26.
22. Jara M, Lanes SF, Wentworth C et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007; 30: 1151–60.
23. Short PM, Williamson PA, Elder DH et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest 2012; 141: 81–6.
24. Lee TA, Wilke C, Joo M et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169 (15): 1403–10.
25. Jara M, Wentworth C, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open 2012; 2 (3).
26. FDA (US) (2009) UCM190463. Available at: http://www.fda. gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary allergydrug sadvisorycommittee/ ucm190463.pdf (accessed 14 October 2011).
27. Santus P, Di Marco F, Radovanovic D, Centanni S. Tiotropium: what came after the UPLIFT study. Expert Opin Pharmacother 2012; 13: 613–8.
28. Singh S, Loke YK, Enrigh PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215.
29. Dong YH, Lin HH, Shau WY et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68 (1): 48–56.
30. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mg via Respimat and 18 mg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010; 104: 228–36.
31. http://www.clinicaltrials.gov/ct2/show/NCT01222533? term=205.458&rank=1 (accessed 4 Feb 2013).
32.  Metzdorf N, Hallmann C, Disse B. Thorax editorial by Jenkins and Beasley related to tiotropium respimat. Thorax published online February 12, 2013. doi: 10.1136/thoraxjnl-2013-203228.
33. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 575–84. Review.
34. Loke YK, Singh S. Risks Associated With Tiotropium in Chronic Obstructive Pulmonary Disease. Overview of the Evidence to Date. Ther Adv in Drug Safe 2012; 3 (3): 123–31.
35. Lelorier J, Gregoire G, Benhaddad A et al. (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337: 536–42.
36. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol 1996; 49: 395–400.

Н.А.Кароли, А.П.Ребров 

Кафедра госпитальной терапии лечебного факультета ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского Минздрава РФ